Skip to main content

Table 1 Dysregulated expression of lncRNAs and their potential clinical implications in ovarian cancer

From: Long non-coding RNAs in ovarian cancer

LncRNA

Differential expression in ovarian carcinoma

Clinical application

References

HOTAIRa

Up

HOTAIR levels were positively correlated with the FIGO stage, histological grade of the tumor, lymph node metastasis. HOTAIR was an independent prognostic factor for OS and DFS in ovarian cancer patients

[37, 38]

HOXA11-ASa

Down in EOC

High HOXA11-AS in SOC expression in tumor tissues was an independent predictor of poor PFS and OS

[40, 41]

Up in SOC

Xista

Down

Reduced expression of Xist in patient samples was correlated with a shorter progression-free interval

[43,44,45]

ANRILa

Up

Elevated ANRIL expression was positive correlated with advanced FIGO stage, high histological grade, lymph node metastasis. ANRIL was an independent prognostic factor for OS.

[54, 55]

MEG3a

Down

No evidence

[61, 62]

HOST2a

Up

No evidence

[64]

FAL1a

Up

FAL1 occurred frequently in epithelial cancer and were associated with clinical outcomes in patients with ovarian cancer

[65]

LSINCT5a

Up

No evidence

[66]

ZNF300P1a

Down

No evidence

[67]

TC1500845, TC0901107

Up

No evidence

[68]

TC0100223, TC0101686

Down

No evidence

TC0101441a

Up

TC0101441 was an independent prognostic factor for OS in ERα-positive ovarian cancer

AB073614a

Up

5-year OS in ovarian cancer patients with high expression of AB073614 was inferior to that with low expression

[73]

ASAP1-IT1

Up

High expression of ASAP1-IT1 and FAM215A were associated with favorable OS

[74]

FAM215A

Up

PVT1a

Up

Low expression levels of PVT1 and lnc-SERTAD2–3 exhibited longer PFS and OS. PVT1, lnc-SERTAD2–3 and hsa-miR-200c-3p simultaneously can stratify patients’ risk of relapse into three discrete classes, high risk, mixed and low risk

[60]

lnc-SERTAD2–3

Up

RP11-284 N8.3.1

Down

RP11-284 N8.3.1 and AC104699.1.1 significantly divide stages III and IV ovarian cancer patients into high- and low-risk groups and their increased expressions were associated with a decreased risk of survival

[77]

AC104699.1.1

Down

AC005562.1, AC105760.2, EPB41L4A-AS1, MCM3AP-AS1

Up

Potential candidates associated with stage progression in ovarian cancer and could classify patients into high-and low-risk subgroups with significantly different survival outcomes

[81]

AC074117.10, MEG8, RP11-220I1.1, RP11-429 J17.2, RP11-618G20.1

Down

AC092214.10, CYP3A5, LEMD1, PART1, RNF157-AS1, RP11-532F12.5

Up

No evidence

[83]

AC010680.1, ADAMTS9-AS1, ADAMTS9-AS2, AK021537, AK125532, GRTP1-AS1, LEMD1-AS1, LOC386758, LOC729970, RP1–7814.1, RP11-597D13.9, LEMD1-AS1

Down

lnc-SOX4–1, lnc-HRCT1–1

Up

Low expression levels of lnc-SOX4–1 and lnc-HRCT1–1 exhibited longer PFS and OS

[60]

RUNX1-IT1, MALAT1

Up

RUNX1-IT1, MALAT1, H19, HOTAIRM1, LOC100190986 and AL132709.8 were associated with OS and DFS

[49]

H19a

Majority expressed in benign, borderline and invasive SOC, but not in epithelial cells of the mucinous tumors

HOTAIRM1, LOC100190986, AL132709.8

Up

SPRY4-IT1

Up

High lncRNA SPRY4-IT1 expression is an independent prognostic factor for PFS and OS

[85]

BC037530, AK021924, AK094536, AK094536, BC062365

Up

Higher expressions of lncRNAs BC037530, AK021924, AK094536, AK094536, BC062365 and lower expressions of lncRNAs BC004123 BC007937 were associated with ovarian cancer patients survival and can serve as an independent predictor apart from FIGO stage and patient grade

[86]

BC004123, BC007937

Down

LOC100288181

Up

High Lnc-OC1 expression was associated with poor prognosis of ovarian cancer patients

[87]

DUXAP10

Up

The overall survival of patients with ovarian cancer whose DUXAP10 was overexpressed was significantly lower than that in the DUXAP10 low expression group. Tumor stage in DUXAP10 high expression group was higher, and the tumor volume was larger.

[88]

  1. a mechanism described in ovarian cancer